a public good project by the
Synthesis
Company
of California

© 2026

John Hynes | doi.page

0 works0 citations0 h-index

John Hynes

Samjin Pharm (South Korea)(KR)Gloucestershire Wildlife Trust(GB)Wildfowl & Wetlands Trust(GB)

Publications by Year

Research Areas

Cytokine Signaling Pathways and Interactions, Melanoma and MAPK Pathways, Chemical Synthesis and Analysis, Asymmetric Synthesis and Catalysis, Crystallization and Solubility Studies

Most-Cited Works

→ Modulation of Receptor and Receptor Subtype Affinities Using Diastereomeric and Enantiomeric Monosaccharide Scaffolds as a Means to Structural and Biological Diversity. A New Route to Ether Synthesis(1998)108 cited
→ Copper-Catalyzed Chlorination of Functionalized Arylboronic Acids(2010)91 cited
→ Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors(2007)81 cited
→ N-Amination of Pyrrole and Indole Heterocycles with Monochloramine (NH₂Cl)(2004)79 cited
→ DBS Sampling Can be Used to Stabilize Prodrugs in Drug Discovery Rodent Studies without the Addition of Esterase Inhibitors(2010)78 cited
→ Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity(2016)73 cited

→ Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005(2005)70 cited

→ Synthesis of Potent Cyclic Hexapeptide NK-1 Antagonists. Use of a Minilibrary in Transforming a Peptidal Somatostatin Receptor Ligand into an NK-1 Receptor Ligand via a Polyvalent Peptidomimetic(1996)60 cited

→ Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases(2010)57 cited

→ Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties(2003)57 cited